Year All2025202420232022202120202019 Jul 24, 2025 Lilly and Verve announce expiration of Verve tender offer Jun 17, 2025 Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk Jun 02, 2025 Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 28, 2025 Verve Therapeutics to Participate in Upcoming Investor Conferences May 14, 2025 Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results May 02, 2025 Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Apr 14, 2025 Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 Apr 11, 2025 Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 Apr 04, 2025 Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Mar 24, 2025 Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
Jun 17, 2025 Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
May 14, 2025 Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results
Apr 14, 2025 Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Apr 11, 2025 Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Mar 24, 2025 Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
